
## **BNSSG Inhaled Steroid Step-Down Protocol in COPD**



The following protocol describes a process for considering whether withdrawal of inhaled corticosteroids may be safe in patients with COPD with FEV1  $\geq$ 40% or  $\leq$ 80% predicted. Patients with FEV1 >80% predicted should be assessed comprehensively to look at the cause of their symptoms and they therefore fall outside the scope of this guideline. Refer to full <u>BNSSG COPD guideline</u> for more information on COPD management.



\* Review historical bloods if available. Only review eosinophil level if patient not taking oral corticosteroids when sample taken.

+ If there is uncertainty about an underlying diagnosis of asthma consider reversibility testing. If FEV1 improves by >12% following a bronchodilator, consider a diagnosis of asthma. Asthmatic features suggesting steroid responsiveness in this context include any previous secure diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time (at least 400 ml) or substantial diurnal variation in peak expiratory flow (at least 20%) Consider stepping down dose of ICS if disease well controlled but do not withdraw. If there is uncertainty about whether the patient has significant reversibility in air flow obstruction e.g., asthma/COPD overlap but step down is still being considered, then weaning inhaled steroids over a period should be considered. Alternatively consider further clarification of the correct diagnosis before changing treatment. Patients must always be advised of what to do should they experience a clinical deterioration after step-down. Approved: December 2024 BNSSG Area Prescribing & Medicines Optimisation Committee. For review: December 2027